Logan Lutton

Health benefit costs for employees are projected to rise 6.7% in 2026—the largest increase in 15 years—as employers grapple with escalating prescription drug prices, growing GLP-1 coverage and a broader push to offer diverse, cost-saving health plan options amid mounting affordability concerns.

Medicaid expansion increased overall PrEP access in the U.S., but significant racial, gender and structural disparities persist, limiting equitable HIV prevention despite rising national uptake.

Sandoz’s Tyruko (natalizumab), the only FDA approved natalizumab biosimilar for adults with relapsing multiple sclerosis and Crohn’s disease, is now available by prescription in the United States under a restricted-distribution program because of the drug’s risk of progressive multifocal leukoencephalopathy.

Here’s what you missed this week on Managed Healthcare Executive.

The investigational lenacapavir-bictegravir tablet has the potential to reduce the pill burden of HIV treatment, according to a recent news release.

The FDA has approved Poherdy as the first interchangeable biosimilar to Perjeta, expanding treatment options for adults with HER2-positive breast cancer across both early-stage and metastatic settings.

In this interview, Lasara Firefox Allen, MSW, shares insights on gender-affirming menopause care, the unique needs of gender-diverse individuals and the importance of educating healthcare providers to offer inclusive support.

Results from two studies show that fenebrutinib significantly reduced relapses and slowed disease progression when compared with currently available treatments.

Veterans in the healthcare workforce are promoted more often and stay longer than non-veteran peers, highlighting their valuable leadership skills amid growing national healthcare staffing shortages.

After reviewing new data that proves hormone replacement therapy does not increase a woman’s risk of receiving a breast cancer diagnosis, the FDA has removed the black box label.

Here’s what you missed this week on Managed Healthcare Executive.

New interim safety and efficacy data for primary biliary cholangitis (PBC) treatment Livdelzi (seladelpar) demonstrates sustained itch relief and the potential to slow disease progression.

Nearly all women experience a decrease in libido as they go through perimenopause and menopause, but it remains unaddressed

Here’s what you missed this week on Managed Healthcare Executive.

Although people are living longer with HIV, patients must still grapple with survivors’ remorse and the challenges of growing older within an ageist society.

Early childhood stressors, like divorce, could increase the risk of developing psoriasis later in life, highlighting the importance of emotional well-being, according to the results of a recent Swedish study.

Cardiovascular, Renal and Metabolic Conditions Increasingly Prevalent, Expensive for Medicare Fee-For-Service Population

Although dry eye disease (DED) affects millions of Americans, there is a lack of effective treatment options and discontinuation rates are high, according to an abstract presented at AMCP Nexus 2025.

An abstract presented at AMCP Nexus 2025 showed that Medicaid drug spend in 10 states in FY 2023 was approximately equal to or less than the national drug spending rate of 14%.

An abstract presented at AMCP Nexus 2025 showed the overuse of opioids following successful cancer treatment is detrimental to patient health and expensive.

Self-injected Brekiya (dihydroergotamine mesylate) is now available by prescription for patients suffering from cluster headaches and migraines with aura.

Fifty-four percent of patients ages 12 to 18 with severe alopecia noticed hair regrowth when given 4-mg of Olumiant (oral baricitinib), according to results of a study presented this week at the 2025 Fall Clinical Dermatology conference.

In this second segment of an interview with Managed Healthcare Executive about this presentation about aesthetic dermatology at the 2025 Fall Clinical Dermatology Conference, Mark S.Nestor, M.D., Ph.D., discussed botulinum toxin injections, the effects that injections into the glalbella can have on depression and differing molecular potencies of the different brands of botulinum toxin.

In this first segment from an interview with Managed Healthcare Executive about his presentation about trends in aesthetic dermatology, the 2025 Fall Clinical Dermatology Conference in Las Vegas, Mark S. Nestor, M.D., Ph.D., talks about the shift away from hyaluronic acid to collagen stimulators, such as poly-L-lactic acid.

Here’s what you missed this week on Managed Healthcare Executive.

Mona Shahriari, M.D., dermatologist at Central Connecticut Dermatology and an associate clinical professor at Yale School of Medicine discusses the highlights of her session called ‘Seeing Clearly: A Visual Guide to Diagnosing Prurigo Nodularis in Skin of Color.’

Determining a biologic's duration of use to treat pediatric atopic dermatitis has several factors, according to Lawrence Eichenfield, M.D., chief of pediatric and adolescent dermatology at Rady Children’s Hospital, San Diego.

Expensive, newer therapies and a lack of pediatric data are roadblocks to advancing treatment for pediatric atopic dermatitis, according to Lawrence Eichenfield, M.D., chief of pediatric and adolescent dermatology at Rady Children’s Hospital, San Diego.

Lawrence Eichenfield, M.D., chief of pediatric and adolescent dermatology at Rady Children’s Hospital, San Diego, gives an overview of his session at the 2025 Fall Clinical Dermatology Conference.

Lawrence Eichenfield, M.D., chief of pediatric and adolescent dermatology at Rady Children’s Hospital, San Diego, discusses why his clinic has shifted towards earlier atopic dermatitis treatment for patients.